Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169474 | 0.80 | HTR2A (0.41) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL171143 | 0.76 | CHRM2 (0.40) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL29814719 | 0.74 | HTR2A (0.37) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL13490658 | 0.73 | SIGMAR1 (0.49) | HTR2C | |
| SCHEMBL171593 | 0.73 | CDK8 (0.40) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL171145 | 0.72 | HTR2A (0.46) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL13490471 | 0.72 | PIM1 (0.47) | CHRM2CHRM3 | |
| SCHEMBL13591415 | 0.71 | CHRM3 (0.49) | HTR2ACHRM2CHRM3 | |
| SCHEMBL171646 | 0.71 | HTR2A (0.41) | HTR2AHTR2CHTR2BCHRM2CHRM3 | |
| SCHEMBL13591416 | 0.71 | HTR2A (0.37) | HTR2AHTR2CHTR2BCHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2426120-A1 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | Fujifilm Finechemicals Co., Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | HTR2A 177/4885HTR2C 399/4885HTR2B 179/4885 |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | QDPR, HRH4, HRH2 | HTR2A 160/4885HTR2C 391/4885HTR2B 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.